Advanced and metastatic PC shows upregulated endothelin type A receptor (ETAR) and reduced endothelin type B receptor (ETBR) expression, therefore sustaining unattenuated ETAR-mediated ET-1 action [17,18], and higher plasma ET-1 levels compared to hormone-naïve cancer [16]. The gene discussed is EDN1; the disease is pachyonychia congenita.